Commentary: Tackling corruption in the life sciences sector
This article was originally published in Scrip
Executive Summary
What is the risk that business practices in life science companies might be found to be corrupt by enforcement agencies? Amy J Conway-Hatcher, Jürgen Beninca and Emma O’Kane of the US-based law firm Morgan Lewis describe some of the potential pitfalls for pharmaceutical executives.